RxDoctor Payments Data

Becca Austin

Women's Health · Little Rock, ARNPI 1063725711

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,642 of the $2,090 with a category attached, or 78.6%. 9 manufacturers reported payments, led by Astellas Pharma US Inc at 27.3% of the total.

$2,090in general payments, 2019–2025

Across 89 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$571
  • Sumitomo Pharma America, Inc.$512
  • AbbVie$393
  • Medtronic$315
  • Urovant Sciences Inc$111
  • 180 Medical, Inc.$84
  • plus $104 from 3 others

What the payments were for

  • Food & beverage$1,64279%
  • Education$44821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc12$571
Sumitomo Pharma America, Inc.32$512
AbbVie20$393
Medtronic12$315
Urovant Sciences Inc5$111
180 Medical, Inc.3$84
Coloplast3$60
Boston Scientific1$25
Pfizer1$18

How this compares

$2,090 in reported general payments places this provider in the 85th percentile of 44 women's health providers in Arkansas.

See all women's health providers in Arkansas

Medicare billing

Part B allowed, 2024
$115,582
Medicare patients
491
Services billed
2,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron349$226,191
MyrbetriqMirabegron415$216,528
Estradiol182$12,378
Trospium Chloride154$8,591
Fosfomycin Tromethamine27$8,487
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst178$3,512
Cephalexin486$3,152
Methenamine Hippurate54$2,851
Solifenacin Succinate32$989
Trimethoprim21$928
Trospium Chloride ErTrospium Chloride11$575
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim55$307
Fluconazole37$225
Ciprofloxacin Hcl47$204
Nystatin18$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$512$226,191349 claims
Astellas Pharma US IncMyrbetriq$571$216,528415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 44 women's health providers in Arkansas.

Other women's health in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →